Gregory M. Glenn

Gregory M. Glenn (chief executive) discloses dealings in 2 companies, chiefly Novavax Inc and Iomai Corp. In total, 502 filings cover trades dated from 14 February 2006 to 10 March 2023.

On the open market, the record shows 28 purchases worth €218k and 361 sales worth €37.5M. Sales outweigh purchases by €37.3M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 16 share grants and 77 option exercises. In 2023 alone, the filings show 3 purchases and no sales.

The median purchase comes to €5,004. Clusters matter here: 5 out of 14 purchases overlapped with buying by a colleague within 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The newest entry dates from 14 March 2023: an open-market purchase of €13k, in Novavax Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.